Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 89 | 18,079 | 44% |
| 2020 | 86 | 19,082 | 47% |
| 2021 | 114 | 26,117 | 51% |
| 2022 | 141 | 33,111 | 54% |
| 2023 | 168 | 36,069 | 57% |
| 2024 | 193 | 48,756 | 59% |
| 2025 from claims | – | 47,711 43,785–50,478 | 59% |
| 2026 forecast | – | 52,842 46,493–60,978 | 60% |
| 2027 forecast | – | 58,500 50,011–69,714 | 60% |
| 2028 forecast | – | 64,756 54,033–79,292 | 61% |
| 2029 forecast | – | 71,674 58,541–89,886 | 61% |
| 2030 forecast | – | 79,322 63,548–101,651 | 62% |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 25% of the cases CMS names in Texas; 93 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 2% inpatient hospital, 20% hospital outpatient, 77% office. The share outside the hospital has moved +30 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~52,800 | ~1,300 | ~10,300 | ~41,200 |
| 2027 · ~58,500 | ~1,500 | ~11,200 | ~45,800 |
| 2028 · ~64,800 | ~1,700 | ~12,200 | ~50,800 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 19% (20% in 2025), office about 79% (77% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 307 | 65,607+28%/yr | +28%/yr | 16.8 | 81% | 135,200 in 2030+13%/yr |
| Georgia | 65 | 14,399+9.3%/yr | +9.3%/yr | 9.7 | 74% | 20,000 in 2030+5.6%/yr |
| Oklahoma | 48 | 11,719+21%/yr | +21%/yr | 16.6 | 72% | 19,200 in 2030+8.6%/yr |
| Tennessee | 38 | 9,735+16%/yr | +16%/yr | 8.3 | 69% | 15,600 in 2030+8.1%/yr |
| Virginia | 47 | 9,709+14%/yr | +14%/yr | 6.5 | 70% | 21,900 in 2030+14%/yr |
| South Carolina | 44 | 8,777+14%/yr | +14%/yr | 8.4 | 72% | 16,300 in 2030+11%/yr |
| Mississippi | 39 | 8,487+28%/yr | +28%/yr | 15.3 | 68% | 14,900 in 2030+9.8%/yr |
| Alabama | 31 | 7,567+19%/yr | +19%/yr | 9.4 | 82% | 11,800 in 2030+7.7%/yr |
| North Carolina | 35 | 7,475+4.4%/yr | +4.4%/yr | 4.4 | 66% | 10,800 in 2030+6.4%/yr |
| Kentucky | 24 | 7,085+18%/yr | +18%/yr | 9.2 | 65% | 11,400 in 2030+8.3%/yr |
| Louisiana | 33 | 6,694+10%/yr | +10%/yr | 9.4 | 82% | 12,700 in 2030+11%/yr |
| Maryland | 25 | 5,850+12%/yr | +12%/yr | 5.3 | 70% | 12,200 in 2030+13%/yr |
| Arkansas | 17 | 4,095+20%/yr | +20%/yr | 7.1 | 73% | 6,940 in 2030+9.2%/yr |
| West Virginia | 12 | 3,280+21%/yr | +21%/yr | 9.3 | 82% | 4,240 in 2030+4.4%/yr |
| Delaware | 5 | 1,763+16%/yr | +16%/yr | 7.8 | 92% | 3,650 in 2030+13%/yr |
| District of Columbia | 4 | 1,007+12%/yr | +12%/yr | 11.6 | 83% | 2,200 in 2030+14%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 1,025 | 283,370+3.6%/yr | +3.6%/yr | 125.01.1× | 51% | 394,700 in 2030+5.7%/yr |
| Bone graft & orthobiologics | 52 | 1,980−11%/yr | −11%/yr | 0.91.4× | 3% | 1,960 in 2030−0.1%/yr |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Kerecis leads with 25% of company spending on these surgeons in 2025, −8 pts on 2024.
In 2025, 34 companies reported engagement with Texas’s surgeons worth $1.5M in consulting, speaking, meals and travel tied to these products, about $7,687 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.